Navigation Links
Portola Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of PRT062607, an Oral, Syk-Specific Inhibitor for Chronic Inflammatory Disease Indications
Date:3/23/2010

SOUTH SAN FRANCISCO, Calif., March 23 /PRNewswire/ -- Portola Pharmaceuticals, Inc. today announced that it has initiated its first in human Phase 1 trial in healthy volunteers of PRT062607, a novel, oral Syk-specific kinase inhibitor in development to treat chronic inflammatory diseases, including rheumatoid arthritis (RA), and certain cancers, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. In preclinical in vivo models of RA, PRT062607 was shown to reduce inflammation in a dose-dependent manner.

PRT062607 is Portola's lead compound discovered from an extensive kinase chemistry effort that has led to the development of potent, oral inhibitors of Spleen Tyrosine Kinase (Syk) and Janus Kinase (JAK).  Syk and JAK play key roles in signaling pathways that modulate inflammation and certain cancers.  PRT062607 has been shown to be a highly specific inhibitor of Syk in a broad panel of in vitro kinase and cellular assays.

"Because of its key role as a mediator in a number of important signaling pathways, specific, low-level Syk inhibition may be ideal for the management of chronic inflammatory diseases, such as RA, and may be better tolerated than less selective kinase inhibitors," said Daniel D. Gretler, M.D., chief medical officer of Portola.  "The initiation of the Phase 1 trial of PRT062607 is an important milestone toward our goal of developing safe and efficacious oral drugs for rheumatoid arthritis and other chronic inflammatory diseases."

The ascending, single-dose Phase 1 study is assessing the safety, pharmacokinetics and pharmcodynamics of oral PRT062607 in up to 48 healthy individuals. The trial is being conducted at a single U.K. site.  It is expected to be completed in the second half of 2010.

Rheumatoid arthritis, a debilitating and degenerative autoimmune disease, affects approximately 1.3 million people, or about 0.6 percent of the U.S. adult population.(1) An inflammatory disease, it causes pain, swelling, stiffness and loss of function in the joints.  Current treatments include corticosteroids, nonsteroidal inflammatory drugs (NSAIDs), methotrexate and injectable biologic response modifiers.  Portola's product candidate, PRT062607, is orally available and could provide an alternative or supplement to currently used agents, if approved.

About Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals develops innovative therapeutics based on targets with established proofs of concept that are designed to provide significant advances over current treatments for cardiovascular disease and inflammation. The company has global development and commercialization agreements with two of the world's leading pharmaceutical companies collectively valued at about $1 billion in upfront and milestone payments plus double-digit royalties on future sales. Betrixaban, its oral direct Factor Xa inhibitor, is licensed to Merck & Co., Inc., and elinogrel, its competitive, reversible P2Y(12) ADP receptor antagonist, is licensed to Novartis. Both are Phase 2 product candidates that have best-in-class features to address the global multi-billion dollar hospital, specialty and chronic care anticoagulant and antiplatelet markets, respectively.

Portola's proprietary pipeline programs are focused on the discovery and development of PRT061103, a thromboxane receptor antagonist, which is targeted to address a significant unmet need as a potential aspirin alternative for patients intolerant to aspirin; PRT064445, a Factor Xa inhibitor antidote to help manage or reverse the bleeding complications in the tens of millions of patients expected to be treated with Factor Xa inhibitors or low-molecular weight heparin worldwide in the next decade; and PRT062607, a novel, oral Syk-specific kinase inhibitor to treat chronic inflammatory diseases, including rheumatoid arthritis, and certain cancers, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. For additional information, visit www.portola.com.

(1) http://www.niams.nih.gov/Health_Info/Rheumatic_Disease/default.asp

SOURCE Portola Pharmaceuticals, Inc.

Back to top

RELATED LINKS
http://www.portola.com

'/>"/>

SOURCE Portola Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention
2. Portola Announces Data Showing Its Anti-Platelet Drug Inhibits Platelets in Clopidogrel (Plavix(R)) Non-Responders
3. Portola Announces Data Presentations Relevant to Its Lead Phase II Antithrombotic Compounds at American Heart Association Scientific Sessions 2008
4. Portola Completes $60 Million Financing to Advance Its Therapeutic Programs
5. Isis Pharmaceuticals to Present at the Barclays Capital 2010 Global Healthcare Conference
6. Amylin Pharmaceuticals to Present at The Barclays Capital 2010 Global Healthcare Conference
7. Astellas Announces Full Slate of Independent Director Nominees for Election at OSI Pharmaceuticals 2010 Annual Stockholders Meeting
8. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2009 Financial Results
9. Poniard Pharmaceuticals Announces $6.3 Million Financing
10. MicuRx Pharmaceuticals Files Investigational New Drug Application for MRX-I
11. Adamas Pharmaceuticals TCAD Therapy Demonstrates Broad Spectrum Activity Against Susceptible and Resistant Strains of Influenza in Animal Models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2017)... July 27, 2017  West Pharmaceutical Services, Inc. (NYSE: ... for the second-quarter 2017 and updated financial guidance for ... Second-Quarter 2017 Highlights Reported net sales ... the prior-year quarter. Net sales at constant currency (organic) ... EPS was $0.51, compared to $0.60 in the prior-year ...
(Date:7/26/2017)... SINGAPORE , July 27, 2017  Radium Medical Aesthetics, a ... LASEMD, designed to delay aging by effectively addressing several skin conditions ... the skin to become rougher and more fragile. The skin becomes ... the unavoidable exposure to the harmful UV rays from the sun ... hyperpigmentation. ...
(Date:7/26/2017)... YORK , July 26, 2017 The ... Annual Prix Galien USA Award Nominees. ... the Prix Galien Award recognizes outstanding biomedical and technology product ... To qualify, each candidate must be U.S. ... last five years and demonstrate tremendous potential to impact human ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... August 18, 2017 , ... As an industry leader, ... webinar, they will present the line of epMotion automated liquid handling system. This ... can automate everyday pipetting tasks. , Ideal for scientists and lab technicians with ...
(Date:8/18/2017)... ... August 18, 2017 , ... Hernandez Insurance Agencies, ... communities throughout the greater DC region, is inaugurating a “New Leash On Life” ... animals and training them to be companions for veterans in need. , The ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... ... and financial planning services to communities in east Texas, is launching a regional ... Tumor Foundation. , Founded in 1991, the Pediatric Brain Tumor Foundation (PBTF) has ...
(Date:8/18/2017)... Saint John, IN (PRWEB) , ... August 18, 2017 , ... ... services to communities in northwest Indiana, is campaigning in support of Campagna Academy in ... Formerly referred to as the “Hoosier Boys’ Town of Indiana,” Campagna Academy is a ...
(Date:8/18/2017)... ... ... The Golseth Agency, a Texas based insurance management and financial planning assistance provider ... organized to provide support to Christina Upchurch and her two children after the loss ... returned from out of town to find her husband passed away and their home ...
Breaking Medicine News(10 mins):